vialauditThe Roundup

affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →

VENDOR MATCHUP · AUDITED

Ion Peptide vs Limitless Biotech

Two audits, side by side. Composite, subscores, shipping, payment, coupons. Ion Peptide takes the higher composite this cycle.

Composite score

HIGHER COMPOSITE
85
OF 100
VENDOR AUDIT

Ion Peptide

US research-peptide vendor with the cleanest COA paper trail in our public-data cohort - 120 Kovera Labs reports across two months at a median 99.93% purity, zero failures, zero identity-mismatch. Coded ION-X SKU naming on a subset of products is worth knowing about.

vs
76
OF 100
VENDOR AUDIT

Limitless Biotech

Limitless Biotech (formerly Limitless Life Nootropics) is the rebranded US vendor at limitlessbiotech.com. Our April 2026 test order returned 96%+ retatrutide purity with clean cross-lab agreement and 2-day US shipping at premium prices. Buyers should weigh that against a pseudonymous owner-of-record, a promo-seeded Trustpilot base, and community scam reports that predate the rebrand.

Subscore breakdown

7 METRICS
METRIC
ION PEPTIDE
LIMITLESS BIOTECH
Composite · weighted avg
85/100
vs
76/100
Purity / COA
95/100
vs
90/100
Shipping · domestic days
3.0d
vs
2.0d
Pricing
75/100
vs
80/100
Support
85/100
vs
60/100
Last tested
2026-05-29
vs
2026-04-15
Payment
card, crypto
vs
crypto, card

Catalog overlap

ONLY ION PEPTIDE
tb-500ghk-cukpvcjc-1295ipamorelintesamorelinsermorelinpt-141aod-9604nad-plusglutathionethymosin-alpha-1klow
BOTH
bpc-157
ONLY LIMITLESS BIOTECH
retatrutidetirzepatide

Active coupons

No active coupon for Ion Peptide this cycle.
15% off
Limitless BiotechEXCLUSIVEVIAL15

15% off first order

USE CODE

Other matchups

ALL COMPARISONS →
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH